Catalent to acquire Juniper Pharmaceuticals

5 Jul 2018

$133 million deal adds European Early Development Center of Excellence to global network.

Catalent has agreed to acquire Juniper Pharmaceuticals, including its Nottingham, UK-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug development and manufacturing capabilities in the US and Europe, the acquisition of Juniper will expand and strengthen Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and will complement its integrated global clinical and commercial supply network.

Catalent to acquire Juniper Pharmaceuticals
Catalent’s acquisition of Jupiter Pharmaceuticals will complement its own early-phase development centers of excellence, such as the one in San Diego (pictured) where Catalent has extensive experience in spray-drying technologies.

“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” commented Jonathan Arnold, President of Catalent Oral Drug Delivery. “Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”

Juniper’s nearly 150 employees have deep scientific expertise in formulation development, and supply, and will augment Catalent’s current portfolio of solid-state screening, preformulation, formulation, analytical, and bioavailability enhancement solutions, including development of spray-dried dispersions, with integrated development, analytical, and clinical manufacturing co-located in its Nottingham facility.

Catalent will continue to support Juniper’s CRINONE (progesterone gel) franchise marketed by Merck KGaA outside of the US. Juniper’s Intravaginal Ring development pipeline was previously licensed to Daré Bioscience, and Catalent will not be involved in the further development of this program. The acquisition of Juniper is subject to certain customary closing conditions, including that a majority of Juniper’s shares are tendered into the offer, and is expected to close in the first quarter of Catalent’s 2019 fiscal year, which began on 1 July 2018.

Like Catalent, Juniper has expertise in solid-state and preclinical formulation screening for lead-candidate selection, phase-appropriate dose-form development, and superior technologies for challenging molecules, which will strengthen and expand on Catalent’s OptiForm Solution Suite platform. Juniper provides bioavailability enhancement solutions for the development of poorly soluble compounds, including nano-milling, spray drying, hot-melt extrusion, lipid-based drug delivery, and cGMP clinical manufacturing, including specialized facilities and controls for potent and controlled substances.

In 2016, Catalent purchased Pharmatek Laboratories, Inc. and has invested in its San Diego facility to create a center of excellence for early drug development on the U.S. West Coast. Earlier this year, Catalent announced that it would invest in its Somerset, New Jersey facility to create a similarly focused center of excellence on America’s East Coast. Juniper will now provide similar capabilities in the UK and will complement Catalent’s multi-site oral manufacturing network to provide pharmaceutical innovators with a comprehensive solution to accelerate their drug development processes.

Read More

Related news

Concept Life Sciences extends GLP accreditation to support regulatory studies

Concept Life Sciences extends GLP accreditation to support regulatory studies

10 Nov 2018

Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries.

Read more 
Sartorius receives award for outstanding performance in its production chain

Sartorius receives award for outstanding performance in its production chain

8 Nov 2018

Company's manufacturing building for laboratory instruments in Göttingen wins the Global Excellence in Operations Award.

Read more 
Record growth at The Wasdell Group

Record growth at The Wasdell Group

7 Nov 2018

Despite Brexit looming, the company's EU & UK business has increased by almost 30% in the last 12 months.

Read more 
bioLIVE to merge with BioProduction Congress for 2019 event

bioLIVE to merge with BioProduction Congress for 2019 event

7 Nov 2018

BioProduction’s content platform will be added to the bioLIVE exhibition, creating one of the world’s largest event hubs for the bio industry.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more 
Croda opens its Centre of Innovation for marine biotechnology

Croda opens its Centre of Innovation for marine biotechnology

5 Nov 2018

The new Centre of Innovation for Marine Biotechnology will accelerate the company’s research and product development program to identify sustainable, natural sources of functional ingredients.

Read more 
Plasticell receives EU funding to advance neurodegenerative disease research

Plasticell receives EU funding to advance neurodegenerative disease research

1 Nov 2018

Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.

Read more 
DSCSA one-month countdown!

DSCSA one-month countdown!

30 Oct 2018

With only a month to go, it really is too late to start trying to develop an in-house solution.

Read more 
Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

Lonza acquires controlling stake in Octane Biotech to further develop Cocoon autologous technology

30 Oct 2018

Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies.

Read more 
Elpis Biomed human cell models could potentially replace animal experiments in drug discovery

Elpis Biomed human cell models could potentially replace animal experiments in drug discovery

28 Oct 2018

OPTi-OX technology allows the company to produce human cells of unprecedented quality, purity, and consistency.

Read more